Preclinical Trial Articles & Analysis

Q. What is your background and experience in the regenerative medicine and stem cell space? How did this lead you to Regeneus? A. I have always had a passion to play a part in improving people’s health and this passion led me to undertaking a Bachelor’s degree of Medical Science at The University of Technology, Sydney (UTS). It was actually Regeneus that led me into the stem ...

By Regeneus Ltd.

PROTAC technology has been in development for more than 20 years. PROTAC proof-of-concept studies date back to 2001, when Crews' team tested the possibility of artificially induced intracellular protein degradation with a peptide that was too large in molecular weight and required cells to penetrate the peptide to improve cell permeability. The discovery of the first small molecule PROTAC and the ...

By Biopharma PEG Scientific Inc

The risk? According to Medicinenet.com, only 5 in 5,000 drugs that enter preclinical testing advance to human trials. And only 1 of these 5 drugs ultimately gets approved for sale, which means the chance for a new drug to make it to market is 1 in 5,000. That’s a lot of R&D ...

By Vistex Inc

Alfa Cytology unveils advanced cancer immunotherapy development services. Alfa Cytology, a renowned services supplier in oncology, has recently introduced its groundbreaking cancer immunotherapy development services. This initiative signifies a major leap forward in the development of more effective cancer therapies, aiming to boost both precision and versatility within treatment paradigms. ...

By Alfa Cytology

Alfa Cytology has launched ovarian cancer therapy development services. Alfa Cytology, a prominent services provider in oncology, has launched its cutting-edge ovarian cancer therapy development services. This significant advancement represents a vital leap in the quest for more precise and effective treatments for ovarian cancer. With the complexities of ovarian cancer treatment becoming ...

By Alfa Cytology

Q. Tell us about your role as a Research Scientist and Project Lead at Regeneus? A. My role is extremely diverse and has evolved over my time at Regeneus. Initially, I was responsible for optimising our product manufacturing processes, including manufacturing products for our preclinical and clinical trials. For example, I provided the data to support preclinical studies that evaluated ...

By Regeneus Ltd.

Alfa Cytology has introduced its advanced drug development services for brain tumors. Alfa Cytology, celebrated for its cutting-edge biotech solutions and extensive tumor research expertise, has recently introduced brain tumor drug development services, designed to empower researchers in understanding the intricacies and unique challenges associated with brain tumors. Brain tumors represent a ...

By Alfa Cytology

Creative Biolabs, as a top-ranked solution provider of antibody-drug conjugate, scheduled a webinar about improved nuclear localization signal-therapeutics, which went live on January 21, 2022. Antibody-drug conjugate (ADC) has gained booming attention in the past 2021, with multiple international strategic purchases and breakthrough results of both preclinical and clinical trials. As a ...

By Creative Biolabs

The scientific realm of biomedicine has witnessed extraordinary evolution in recent years, particularly in the spheres of cell and gene therapies. These therapies have radically revamped disease treatment modalities, transcending traditional approaches to become some of the most groundbreaking advancements in modern healthcare. This article aims to engage in an incisive analysis of cell and gene ...

By Creative Bioarray

In recent years, adeno-associated virus (AAV) particles have emerged as a pivotal tool in the realm of gene therapy, offering researchers and clinicians innovative approaches to treat a variety of genetic disorders. Premade AAV particles represent a significant advancement in this field, streamlining the process of gene delivery and significantly enhancing the efficiency and efficacy of ...

By Creative Biogene

Abstract This review will illustrate the process of moving from an idea through preclinical research and Galenic developments into clinical investigations and finally to approval by regulatory agencies within the European Union. The two new treatment strategies described, levodopa/carbidopa intestinal gel and levodopa/carbidopa microtablets, for advanced Parkinson's disease, have been ...

By Sensidose AB

There is a growing need to address the high failure rate of drug candidates as they progress through clinical trials. Altis Biosystems aims to bring its technological advances to the forefront, enabling the drug development process to more effectively translate results from preclinical experiments to late-stage clinical trials. Breaking the Conformity of Inadequate Testing Platforms The ...

By Altis Biosystems

Biotech company Nuritas speeds up ingredient discovery in nutrition through AI, using techniques from the pharmaceutical industry where innovation and investment rates are much higher. Through its bioactive peptide finder, Magnifier NπΦ, the company can boast a clinical trial success rate of 80%. Development of an ingredient goes through three phases, from discovery to preclinical biology ...

By Nuritas Ltd.

The scientific realm of biomedicine has witnessed extraordinary evolution in recent years, particularly in the spheres of cell and gene therapies. These therapies have radically revamped disease treatment modalities, transcending traditional approaches to become some of the most groundbreaking advancements in modern healthcare. This article aims to engage in an incisive analysis of cell and gene ...

By Creative Bioarray

VersaWrap as a Protective Interface Background: Fibrous scar tissue between tendon and the surrounding tissue is a common complication following flexor tendon repair. Several factors contribute to scar tissue formation, including damage to the tendon sheath, suture placement, and tendon immobilization. Scar tissue formation results in increased work of flexion (WOF) and contracture formation, ...

By Alafair Biosciences, Inc.

Alfa Cytology has announced its small molecule drug development to advance preclinical cancer research. Alfa Cytology, a comprehensive biotech company specializing in cancer research, has recently announced the cancer small molecule drug development services. The services tend to accelerate the discovery and optimization of molecule drugs with a strict quality control system. Small molecule drugs ...

By Alfa Cytology

In the world of pharmaceuticals, developing safe and effective drugs is a complex and time-consuming process. Before a new drug candidate can progress to clinical trials and ultimately reach the market, it needs to undergo rigorous testing in various model systems to assess its efficacy and safety. One critical component of this evaluation is the use of preclinical animal models. Preclinical ...

By Creative Bioarray

Nuritas has discovered two ingredients called PeptiYouth and PeptiStrong that can be integrated into everyday products, including serums and supplements, to fight the effects of aging on skin and muscles. The company names stem cell aging as a growing focus for start-ups. It also says one of consumers’ most significant concerns is combating the adverse effects of aging. Nuritas uses its ...

By Nuritas Ltd.

The quest for effective therapeutics begins long before a drug reaches clinical trials. One of the cornerstones of this process is drug screening in animal models, which plays a pivotal role in evaluating the safety and efficacy of potential treatments. Animal models offer researchers valuable insights that cannot be obtained through in vitro studies alone, bridging the gap between laboratory ...

By Creative Biogene

Interventional Systems finished the implementation of the IraSME project “E-GantryMate: Compact MR-compatible device for MRI-guided percutaneous needle interventions”. The project kick-off meeting took place in October 2019 at the company’s office in Wattens, Austria. It aimed at expanding and motorizing the MR-compatible manual targeting device previously developed by INS ...

By Interventional Systems (iSYS)